Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Protein Import into the Peroxisomes01:27

Protein Import into the Peroxisomes

Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world use of Cenobamate in pediatric drug-resistant epilepsy: A European multicenter retrospective study.

Epilepsia open·2026
Same author

Diagnosis and management guidelines for infantile epileptic spasms syndrome around the world: A scoping review and comparative study of international approaches.

Epilepsia·2026
Same author

Interview with Jeffrey A. Mensah, recipient of the 2026 Epilepsia Prize for basic science research.

Epilepsia·2026
Same author

Interview with Lennart N. Kersting, recipient of the 2026 Epilepsia Prize for clinical research.

Epilepsia·2026
Same author

Burst-Suppression EEG in Early Infantile Developmental and Epileptic Encephalopathies: Phenotype, Genotype, and Outcome.

Neurology·2026
Same author

Listening across frequencies: Capturing seizures of all patients to advance antiseizure medication development.

Epilepsia·2026

Related Experiment Video

Updated: May 30, 2026

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Fatty acid oxidation and epilepsy.

Stéphane Auvin1

  • 1Inserm, U676, Paris, France. auvin@invivo.edu

Epilepsy Research
|August 23, 2011
PubMed
Summary

The ketogenic diet (KD) effectively treats epilepsy. Polyunsaturated fatty acids (PUFA) show promise in enhancing KD

Area of Science:

  • Neuroscience
  • Nutritional Science
  • Biochemistry

Background:

  • The ketogenic diet (KD), a high-fat, low-carbohydrate regimen, is recognized for treating refractory epilepsy.
  • Lipids, especially fatty acids, are primary caloric sources in the KD, with the high-fat content potentially contributing to anticonvulsant effects.
  • Polyunsaturated fatty acids (PUFA) have demonstrated anticonvulsant properties experimentally, yet clinical trials in epilepsy have yielded inconclusive results.

Purpose of the Study:

  • To investigate the potential role of polyunsaturated fatty acids (PUFA) in supporting the efficacy of the ketogenic diet (KD).
  • To explore the mechanisms by which PUFA might exert anticonvulsant effects within the context of the KD.

Main Methods:

  • Review of experimental studies investigating the anticonvulsant properties of PUFA.

Related Experiment Videos

Last Updated: May 30, 2026

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

  • Analysis of proposed mechanisms, including alterations in central nervous system (CNS) cell membrane composition, nuclear receptor (e.g., PPAR) stimulation, and anti-inflammatory effects.
  • Comparison of experimental findings with clinical trial outcomes in epilepsy.

    • Main Results:

    • Experimental data suggest PUFA may enhance the anticonvulsant efficacy of the KD.
    • Potential mechanisms for PUFA's anticonvulsant action include modifying CNS cell membranes, activating nuclear receptors like PPAR, and reducing inflammation.
    • A discrepancy exists between experimental evidence for PUFA's anticonvulsant effects and the lack of positive results in clinical epilepsy trials.

    Conclusions:

    • Further research is essential to validate the role of PUFA in the ketogenic diet for epilepsy treatment.
    • Understanding the precise mechanisms of PUFA action could lead to improved KD formulations or more flexible dietary protocols.
    • The findings highlight the need for more studies to bridge the gap between experimental and clinical observations regarding PUFA and KD efficacy.